{
    "nct_id": "NCT05451849",
    "official_title": "A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer",
    "inclusion_criteria": "* Patient is > 18 years of age at the time the Informed Consent is signed.\n* Patient has a pathologically confirmed diagnosis of either MPM, Serous Ovarian Adenocarcinoma, Pancreatic Adenocarcinoma, TNBC, and Colorectal Cancer\n* Patient's tumor has been reviewed with confirmed positive MSLN expression on >/= 50% of tumor cells that are 1+, 2+ and/or 3+ by immunohistochemistry. Patients with epithelioid MPM, confirmation of MSLN expression is not required prior to enrollment.\n* Prior to TC-510 infusion, patients must have received at least 1 but no more than 5 systemic therapies for metastatic or unresectable disease with more details provided in the protocol\n* Patients has an ECOG performance status 0 or 1\n* Patient is fit for leukapheresis and has adequate venous access for the cell collection.\n* Patient must have adequate organ function as indicated by the laboratory values in the clinical protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to follow the procedures of the study\n* Known or suspected non-compliance, drug, or alcohol use",
    "miscellaneous_criteria": ""
}